Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Pfizer (PFE) Stock Price

Press coverage about Pfizer (NYSE:PFE) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pfizer earned a news impact score of 0.07 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.4062394038347 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern’s rankings:

A number of equities research analysts have commented on PFE shares. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a report on Wednesday, September 13th. BMO Capital Markets reissued a “buy” rating and issued a $37.00 target price on shares of Pfizer in a report on Thursday, September 14th. Jefferies Group set a $37.00 target price on Pfizer and gave the company a “neutral” rating in a report on Monday, September 18th. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Finally, Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $35.00 to $39.00 in a report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. Pfizer has a consensus rating of “Buy” and an average price target of $38.83.

Pfizer (NYSE:PFE) traded up $0.09 on Thursday, reaching $36.56. The company’s stock had a trading volume of 14,330,000 shares, compared to its average volume of 15,770,000. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market cap of $217,920.00, a PE ratio of 22.43, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01. Pfizer has a 52 week low of $30.90 and a 52 week high of $37.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.61 EPS. equities research analysts predict that Pfizer will post 2.59 EPS for the current year.

Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is presently 78.53%.

In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold a total of 29,450 shares of company stock valued at $1,065,220 in the last quarter. Company insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Pfizer (PFE) Stock Price” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://stocknewstimes.com/2018/01/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-pfizer-pfe-stock-price.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Insider Buying and Selling by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply